Literature DB >> 20881952

Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.

S H James1, R J Whitley.   

Abstract

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are members of the Herpesviridae family and are characterized by their ability to establish latency after primary infection and subsequently reactivate. HSV infections in the neonatal and pediatric populations range from uncomplicated mucocutaneous diseases to severe, life-threatening infections involving the central nervous system (CNS). The antiviral agent acyclovir has significantly improved treatment outcomes of HSV infections, including the frequency of mucocutaneous recurrences and mortality associated with CNS and disseminated infections.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20881952      PMCID： PMC3685871          DOI： 10.1038/clpt.2010.192

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  27 in total

1.  Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity.

Authors: 
Journal:  N Engl J Med       Date:  1975-03-20       Impact factor: 91.245

2.  ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.

Authors:  Koji Chono; Kiyomitsu Katsumata; Toru Kontani; Masayuki Kobayashi; Kenji Sudo; Tomoyuki Yokota; Kenji Konno; Yasuaki Shimizu; Hiroshi Suzuki
Journal:  J Antimicrob Chemother       Date:  2010-06-09       Impact factor: 5.790

3.  Herpesvirus infections of the human central nervous system.

Authors:  L C Olson; E L Buescher; M S Artenstein; P D Parkman
Journal:  N Engl J Med       Date:  1967-12-14       Impact factor: 91.245

4.  Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.

Authors:  D W Kimberlin; C Y Lin; R F Jacobs; D A Powell; L Corey; W C Gruber; M Rathore; J S Bradley; P S Diaz; M Kumar; A M Arvin; K Gutierrez; M Shelton; L B Weiner; J W Sleasman; T M de Sierra; S Weller; S J Soong; J Kiell; F D Lakeman; R J Whitley
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

Review 5.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Authors:  Christian Gilbert; Julie Bestman-Smith; Guy Boivin
Journal:  Drug Resist Updat       Date:  2002-04       Impact factor: 18.500

6.  Vidarabine therapy of neonatal herpes simplex virus infection.

Authors:  R J Whitley; A J Nahmias; S J Soong; G G Galasso; C L Fleming; C A Alford
Journal:  Pediatrics       Date:  1980-10       Impact factor: 7.124

Review 7.  Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.

Authors:  Stephen K Tyring; David Baker; Wendy Snowden
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

Review 8.  Herpes simplex virus infection.

Authors:  Richard J Whitley
Journal:  Semin Pediatr Infect Dis       Date:  2002-01

9.  Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

Authors:  Stephanie L Ciesla; Julissa Trahan; W Brad Wan; James R Beadle; Kathy A Aldern; George R Painter; Karl Y Hostetler
Journal:  Antiviral Res       Date:  2003-08       Impact factor: 5.970

10.  Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.

Authors:  Spotswood L Spruance; Robert Nett; Thomas Marbury; Ray Wolff; James Johnson; Theodore Spaulding
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191
View more
  6 in total

1.  Herpes simplex virus type 1: an atypical presentation of primary infection.

Authors:  Inês Medeiros; Cristiana Maximiano; Teresa Pereira; Maria Miguel Gomes
Journal:  BMJ Case Rep       Date:  2018-04-27

Review 2.  Strength in diversity: Understanding the pathways to herpes simplex virus reactivation.

Authors:  Jon B Suzich; Anna R Cliffe
Journal:  Virology       Date:  2018-07-14       Impact factor: 3.616

3.  Venom Components of Iranian Scorpion Hemiscorpius lepturus Inhibit the Growth and Replication of Human Immunodeficiency Virus 1 (HIV-1).

Authors:  Rezvan Zabihollahi; Kamran Pooshang Bagheri; Zohreh Keshavarz; Fatemeh Motevalli; Golnaz Bahramali; Seyed Davar Siadat; Seyed Bahman Momen; Delavar Shahbazzadeh; Mohammad Reza Aghasadeghi
Journal:  Iran Biomed J       Date:  2016-09-04

Review 4.  Re-thinking lactation-related nipple pain and damage.

Authors:  Pamela Douglas
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 5.  Mitochondrial changes associated with viral infectious diseases in the paediatric population.

Authors:  Sonia Romero-Cordero; Antoni Noguera-Julian; Francesc Cardellach; Clàudia Fortuny; Constanza Morén
Journal:  Rev Med Virol       Date:  2021-03-31       Impact factor: 11.043

6.  RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions.

Authors:  Amanda Perse da Silva; Juliana Freitas Lopes; Vanessa Salete de Paula
Journal:  Braz J Infect Dis       Date:  2014-05-15       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.